Effects of Resveratrol on Benign Prostatic Hyperplasia by the Regulation of Inflammatory and Apoptotic Proteins

被引：23

作者：

Chung, Kyung-Sook ^{[1
]}

Cheon, Se-Yun ^{[1
]}

An, Hyo-Jin ^{[1
]}

机构：

[1] Sangji Univ, Coll Oriental Med, Dept Pharmacol, Gangwon Do 220702, South Korea

来源：

JOURNAL OF NATURAL PRODUCTS | 2015年 / 78卷 / 04期

关键词：

CELL-DEATH; DISEASE; PROTECTS; GRAPES; GROWTH;

D O I：

10.1021/np500810c

中图分类号：

Q94 [植物学];

学科分类号：

071001 ;

摘要：

Resveratrol (1) is a natural polyphenolic compound that has cardioprotective, anticancer, and anti-inflammatory properties. Although diverse biological studies of compound 1 have been conducted, no antiproliferative effects of 1 have been reported in benign prostatic hyperplasia (BPH). BPH is a progressive disease related to inflammation and an imbalance in cell growth and apoptosis. The aims of this study were to determine whether 1suppressed BPH progression in rats and to explore the underlying mechanisms related to regulation of inflammation and apoptosis. Compound 1 treatment decreased prostate weight and cell proliferation in this animal model and markedly decreased BPH-related upregulation of iNOS and COX-2 protein expression. In addition, 1 induced Bax expression and suppressed Bcl-2 and Bcl-xL expressions. Furthermore, 1 triggered caspase-3 activation and decreased levels of its substrate, PARP-1. These results suggested that 1 produced an antiproliferative effect by regulating the expression levels of proteins involved in inflammation and apoptosis during BPH.

引用

页码：689 / 694

页数：6

共 31 条

[1]

ALISON MR, 1992, J ROY COLL PHYS LOND, V26, P25

[2] RETRACTED: Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia (Retracted Article) [J].

Altavilla, D. ;

Minutoli, L. ;

Polito, F. ;

Irrera, N. ;

Arena, S. ;

Magno, C. ;

Rinaldi, M. ;

Burnett, B. P. ;

Squadrito, F. ;

Bitto, A. .

BRITISH JOURNAL OF PHARMACOLOGY, 2012, 167 (01) :95-108

[3] Established Medical Therapy for Benign Prostatic Hyperplasia [J].

Auffenberg, Gregory B. ;

Helfand, Brian T. ;

McVary, Kevin T. .

UROLOGIC CLINICS OF NORTH AMERICA, 2009, 36 (04) :443-+

[4]

Bradamante S, 2004, CARDIOVASC DRUG REV, V22, P169

[5] The role of dihydrotestosterone in benign prostatic hyperplasia [J].

Carson, C ;

Rittmaster, R .

UROLOGY, 2003, 61 (04) :2-7

[6] Inflammation and benign prostatic hyperplasia: Clinical implications [J].

Chughtai B. ;

Lee R. ;

Te A. ;

Kaplan S. .

Current Urology Reports, 2011, 12 (4) :274-277

[7] The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study [J].

Coyne, Karin S. ;

Sexton, Chris C. ;

Thompson, Christine L. ;

Milsom, Ian ;

Irwin, Debra ;

Kopp, Zoe S. ;

Chapple, Christopher R. ;

Kaplan, Steven ;

Tubaro, Andrea ;

Aiyer, Lalitha P. ;

Wein, Alan J. .

BJU INTERNATIONAL, 2009, 104 (03) :352-360

[8] Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: A retrospective analysis [J].

Di Silverio, F ;

Gentile, V ;

De Matteis, A ;

Mariotti, G ;

Giuseppe, V ;

Luigi, PA ;

Sciarra, A .

EUROPEAN UROLOGY, 2003, 43 (02) :164-175

[9] Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: A prospective, randomized, double-blind, placebo-controlled study [J].

Falahatkar, Siavash ;

Mokhtari, Gholamreza ;

Pourreza, Farshid ;

Asgari, Seyed Alaeddin ;

Kamran, Alireza Noshad .

UROLOGY, 2008, 72 (04) :813-816

[10] Role of Apoptosis in disease [J].

Favaloro, B. ;

Allocati, N. ;

Graziano, V. ;

Di Ilio, C. ;

De Laurenzi, V. .

AGING-US, 2012, 4 (05) :330-349

← 1 2 3 4 →